Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 2
Submit an article Journal homepage
103
Views
32
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for ovarian cancer

Lloyd R KellandSt Georges Hospital Medical School Antisoma Research Laboratories, Cranmer Terrace, London, SW17 0QS, UK Tel: +44 (0)208 772 4393; Fax: +44 (0)208 767 1809;E-mail: [email protected]
Pages 413-424 | Published online: 10 May 2005

Bibliography

  • REEDY M, GALLION H, FOWLER JM, KRYSCIO R, SMITH SA: Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. (2002) 85:255–259.
  • HESS V, AHERN R, NASIRI N et al.: Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. Clin. Oncol. (2004) 22:1040–1044.
  • •Study indicating that mucinous ovarian cancer may be considered separate from serous and other ovarian cancer subtypes in terms of response to chemotherapy.
  • MCGUIRE WP HOSKINS WI, BRADY MF et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl. J. Med. (1996) 334:1–6.
  • ••Pivotal Phase III trial showing survivalbenefit of paclitaxel (with cisplatin) versus cydophosphamide (with cisplatin).
  • OZOLS RF, BUNDY BN, GREER BE et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. (2003) 21:3194–3200.
  • •Phase III showing noninferiority of carboplatin (with paclitaxel) versus cisplatin (with paclitaxel).
  • GORE ME, FRYATT I, WILTSHAW E, DAWSON T: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. (1990) 36:207–211.
  • MARKMAN M, ROTHMAN R, FIAKES T et al.: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. j Clin. Oncol. (1991) 9:389–393.
  • ADAMS M, CALVERT AH, CARMICHAEL J et al.: Chemotherapy for ovarian cancer — a consensus statement on standard practice. Br. J. Cancer (1998) 78:1404–1406.
  • PICCART MJ, BERTELSEN K, JAMES K et al.: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. (2000) 92:699–708.
  • THE ICON COLLABORATORS : Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet (2002) 360:505–515.
  • MUGGIA FM, BRALY PS, BRADY MF et al.: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. Clin. Oncol. (2000) 18:106–115.
  • THE ICON AND AGO COLLABORATORS: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 361:2099–2106.
  • ••Pivotal multi-centre trial showing survivalbenefit by adding paclitaxel to cisplatin in patients relapsing > 6 months after initial therapy.
  • MARKMAN M, LIU PY, WILCZYNSKI S et al.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. (2003) 21:2460–2465.
  • MICHA JP, GOLDSTEIN BH, MATTISON JA et al.: Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol. Oncol (2005) 96:132–135.
  • SPRIGGS DR, BRADY M, RUBIN S et al.: A Phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (G0G162). Proc. ASCO (2004) 22:A5004.
  • HARRIES M, MOSS C, PERREN T et al.: A Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br. J. Cancer (2004) 91:627–632.
  • GARCIA AA, O'MEARA A, BAHADOR A et al.: Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol. Oncol (2004) 93(2):493–498.
  • KIKUCHI Y, SAKAMOTO H, YAIVIAMOTO K: Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy. Int. J. Gynecol. Cancer (2005) 15(1):45–49.
  • ALBERTS DS, JIANG C, LIU PY, WILCZYNSKI S, MARKMAN M, ROTHENBERG ML: Long-term follow-up of a Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int. J. Gynecol. Cancer (2004) 14:224–228.
  • CHAN JK, LOIZZI V, MANETTA A, BERMAN ML: Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol. Oncol (2004) 92:368–371.
  • KELDSEN N, HAVSTEEN H, VERGOTE I, BERTELSEN K, JAKOBSEN k Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a Phase II study. Gynecol. Oncol (2003) 88:118–122.
  • MARKMAN M, BLESSING JA, MOORE D, BALL H, LENTZ SS: Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian carcinoma: a GOG Phase II trial. Clin. Oncol (1998) 69:226–229.
  • MUGGIA FM, HAINS WORTH JD, JEFFERS S et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Clin. Oncol (1997) 15:987–993.
  • GORDON AN, FLEAGLE JT, GUTHRIE D, PARKIN DE, GORE ME, LACAVE AJ: Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. j Clin. Oncol. (2001) 19:3312–3322.
  • GORDON AN, TONDA M, SUN S, RACKOFF W: Doxil Study 30-49 Investigators: long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase III randomized study of recurrent and platinum refractory epithelial ovarian cancer. Gynecol. Oncol (2004) 95:1–8.
  • ••Long-term follow-up and survival analysisshowing advantage of pegylated liposomal doxorubicin versus topotecan as second-line treatment.
  • THIGPEN JT, AGHAJANIAN CA, ALBERTS DS et al.: Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol. Oncol (2005) 96:10–18.
  • FERRARO J-M, WEBER B, LEPILLE D et al.: Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (> 6 months) relapse (AOCLR): survival results of a GINECO Phase II trial. Proc. ASCO (2004) 22:A5022.
  • MCGUIRE WP, BLESSING JA, BOOKMAN Mk LENTZ SL, DUNTON CJ: Topotecan has substantial antitumor activity as firt-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol (2000) 18:1062–1067.
  • AHMAD T, GORE M: Review of the use of topotecan in ovarian carcinoma. Expert Opin. Pharmacother. (2004) 5:2333–2340.
  • LEVY T, INBAR M, MENCZER J, GRISARU D, GLEZERIVIAN M, SAFRA T: Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol. Oncol (2004) 95:686–690.
  • BHOOLA SM, COLEMAN RL, HERZOG T et al.: Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol (2004) 95:564–569.
  • CLARKE-PEARSON DL, VAN LE L, IVESON T et al.: Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J. Clin. Oncol (2001) 19:3967–3975.
  • PFISTERER J, PLANTE M, VERGOTE I et al.: Gemcitabine/carboplatin (GC) versus carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized Phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc. ASCO (2004) 22:A5005.
  • •Important new data showing a significant gain in progression-free survival by adding gemcitabine to carboplatin, second-line, in patients with platinum-sensitive recurrent cancer; awaiting publication of full paper.
  • CHRYSTAL K, STEER CB, CHEONG KA et al.: Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first-line therapy for patients with advanced epithelial ovarian cancer. A Phase II trial of sequential doublets. (GO-FIRST). Proc. ASCO (2004) 22:A5034.
  • ROSE PG, BLESSING JA, MAYER AR,HOMESLEY HD: Prolonged oral etoposide as second-line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a GOG study. J. Clin. Oncol (1998) 16:405–410.
  • VAN DER BURG ME, DE WIT R, VAN PUTTEN WL et al.: Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br. J. Cancer (2002) 86:19–25.
  • •Indication that prolonged oral etoposide may offer utility second-line in patients with platinum-resistant disease.
  • VASEY PA, JAYSON GC, GORDON A et al.: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. (2004) 96:1682–1691.
  • •Indication that another taxane, docetaxel, possesses promising activity (similar to paclitaxel in terms of progression-free survival) when used first-line with carboplatin.
  • SORENSEN P, HOYER M, JAKOBSEN A, MALMSTROM H, HAVSTEEN H, BERTELSEN K: Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol. Oncol. (2001) 81:58–62.
  • •Indication that alternative platinum-containing agent, oxaliplatin, when combined with paclitaxel has promising activity second-line in patients with platinum-sensitive disease.
  • AEBI S, KURDI-HAIDAR B, GORDON R et al.: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. (1996) 56:3087–3090.
  • VIENS P, PETIT T, YOVINE A et al.: Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) in platinum + taxanes sensitive advanced ovarian cancer (AOC) patients: final results. Proc. ASCO (2004) 22:A5023.
  • FERRANDINA G, LUDOVISI M, DAGOSTINO G et al.: Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer. Proc. ASCO (2004) 22:A5078.
  • FRACASSO PM, BLESSING JA, MORGAN MA, SOOD AK, HOFFMAN JS: Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a Gynecologic Group study. J. Clin. Oncol. (2003) 21:2856–2859.
  • GORE ME, ATKINSON RJ, THOMAS H et al.: Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. Eur. Cancer (2002) 38:57–512.
  • KRISTENSEN GB, VERGOTE I, EISENHAUER E et al.: First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC versus TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival. Proc. ASCO (2004) 22:A5003.
  • DU BOIS A. COMBE M, ROCHON J et al.: Epirubicin/paclitaxel/carboplatin (TEC) versus paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (0C) FIGO stages IIB-IV. An AGO-GINECO Intergroup Phase III trial. Proc. ASCO (2004) 22:A5007.
  • HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57–70.
  • ALBERTS DS, LIU PY, HANNIGAN EV et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl. J. Med. (1996) 335:1950–1955.
  • PICCART MJ, FLOQUET A, SCARFONE G et al.: Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized Phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int. J. Gynecol. Cancer (2003) 13:196–203.
  • MARKMAN M, BUNDY BN, ALBERTS DS et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. (2001) 19:1001–1007.
  • •Superior progression-free survival for intraperitoneal cisplatin arm.
  • CANNISTRA SA, BAST RC, BEREK JS et al.: Progress in the management of Gynecologic Cancer: consensus summary statement. J. Clin. Oncol. (2003) 21:129s–132s.
  • KELLAND LR: Overcoming resistance toplatinum therapy in patients with advanced cancer. Am. J. Cancer (2002) 1:247–255.
  • AGARWAL R, KAYE SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer (2003) 3:502–516.
  • HOLZER AK, KATANO K, KLOMP LWJ, HOWELL SB: Cisplatin rapidly down-regulates it own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res. (2004) 10:6744–6749.
  • ROSEN LS, LAXA B, BOULOS L et al.: Phase I study of TLK286 (Telcyta) administered weekly in advanced malignancies. Clin. Cancer Res. (2004) 10:3689–3698.
  • •First full paper (Phase I) of the glutathione transferase-activated prodrug TLK-286.
  • KAVANAGH J, LEWIS L, CHOI H et al.: Phase I-2a study of TLK286 (a novel glutathione analog) in combination with carboplatin in platinum refractory or resistant (> 3rd line) ovarian cancer. Proc. ASCO (2004) 22:A5060.
  • BROWN GL, LEWIS L, CHOI H et al.:Phase I-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with liposomal doxorubicin in platinum refractory or resistant ovarian cancer. Proc. ASCO (2004) 22:A5062.
  • PLUMB JA, STRATHDEE G, SLUDDEN J, KAYE SB, BROWN R: Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLHI gene promoter. Cancer Res. (2000) 60:6039–6044.
  • STRATHDEE G, MACKEEN MJ, ILLAND M, BROWN R: A role for methylation of the hMLHI promoter in loss of hHMLHI expression and drug resistance in ovarian cancer. Oncogene (1999) 18:2335–2341.
  • SHIH I-M, KURMAN RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. (2004) 164:1511–1518.
  • YANAIHARA N, NISHIOKA M, KOHNO T et al.: Reduced expression of MY0I8B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer. Int. J. Cancer (2004) 112:150–154.
  • RUSTIN GJ: Can we now agree to use thesame definition to measure response according to CA-125? J. Clin. Oncol. (2004) 22:4035–4036.
  • PAUTIER P, JOLY F, KERBRAT P et al.:Preliminary results of a Phase II study to evaluate gefitinib (ZD1839) combined with paclitaxel (P) and carboplatin (C) as second-line therapy in patients (pts) with ovarian carcinoma (0C). Proc. ASCO (2004) 22:A5015.
  • LOIBL S, DU BOIS A, PFISTERER J et al.: Safety, tolerability and activity of gefitinib (ZD1839) in combination with tamoxifen in ovarian cancer patients refactory to platinum-taxane based therapy-a Phase II study of the Ovarian Cancer Study Group (AGO Ovar 2.6). Proc. ASCO (2004) 22:A5016.
  • MAVROUDIS D, EFSTATHIOU E, POLYZOS A et al.: A Phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC). Proc. ASCO (2004) 22:A5020.
  • VASEY P, KAYE S, PAUL J et al.: A Phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers. Proc. ASCO (2004) 22:A5017.
  • CAMPOS SM, SEIDEN MV, OZA A et al.: A Phase II, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. Proc. ASCO (2004) 22:A5054.
  • KELLAND LR: Targeting established tumor vasculature: a novel approach to cancer treatment. Curr. Cancer Ther. Rev. (2005) 1:1–9.
  • BEREK JS, TAYLOR PT, GORDON A et al.: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. (2004) 22:3507–3516.
  • SEIDEN MV, BENIGNO BB: The SMART study investigator group: a pivotal Phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC). Proc. ASCO (2004) 22:A5008.
  • ALVAREZ RD, HUH WK, KHAZAELI MB et al.: A Phase I study of combined modality (90) Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. (2002) 8:2806–2811.
  • MEREDITH RF, ALVAREZ RD, PARTRIDGE EE et al.: Intraperitoneal radioimmunochemotherapy of ovarian cancer: a Phase I study. Cancer Biother. Radiopharm. (2001) 16:305–315.
  • ANDERSSON H, ELGQVIST J, HORVATH G et al.: Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin. Cancer Res. (2003) 9:3914S–3921S.
  • YOUNG RC, BRADY MF, NIEBERG RK et al.: Adjuvant treatment for early ovarian cancer: a randomized Phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin- a gynecologic oncology group study. J. Clin. Oncol (2003) 21:4350–4355.
  • SHAYESTEH L, LU Y, KUO WL et al.: PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. (1999) 21:99–102.
  • ••First paper to implicate the PI3K pathwayin ovarian cancer.
  • CAMPBELL IG, RUSSELL SE, CHOONG DY et al.: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. (2004) 64:7678–7681.
  • YUAN ZQ, SUN M, FELDMAN RI et al.: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-0H kinase/Akt pathway in human ovarian cancer. Oncogene (2000) 19:2324–2330.
  • ALTOMARE DA, WANG HQ, SKELE KL et al.: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 23:5853–5857.
  • SINGER G, OLDT RI, COHEN Y et al.: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Nail Cancer Inst. (2003) 95:484–486.
  • •Paper showing relative importance of mutations in BRAF and KRAS in ovarian cancer carcinogenesis.
  • ONO K, TANAKA T, TSUNODA T et al.: Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. (2000) 60:5007–5011.
  • SCHWARTZ DR, KARDIA SL, SHEDDEN KA et al.: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. (2002) 62:4722–4729.
  • WELSH JB, ZARRINKAR PP, SAPINOSO LM et al.: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Nail. Acad. Sci. USA (2001) 98:1176–1181.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.